Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Wednesday, October 5, 2016

Will Tclena Become A Big Player In Multiple Sclerosis?


                                                                  
  

Click here to receive MS news via e-mail



October 4, 2016

Summary

Data of their lead product will be published any day now.
Competitors failed with their studies in SPMS.
Market cap of only $20 million.
In February 2014 I wrote an article about Opexa Therapeutics (NASDAQ:OPXA). Opexa is a small biotech stock working on their T-cell immunotherapy, Tcelna, which is in development for Secondary Progressive Multiple Sclerosis (SPMS).
The market cap of Opexa at that time was $45 million. Today the market cap is $22 million. Obviously the stock hasn't performed well...
What's interesting is that Opexa now is on the eve of publishing the Phase IIb results, scheduled for early Q4 2016, of its lead product in its pipeline: Tcelna.
Tclena
According to the company's website,
The lead product in the pipeline is Tcelna. In MS patients, the faulty immune system is not able to prevent the attack of a small sub-population of myelin reactive T-cells (MRTCs). Opexa's strategy is to identify which specific antigens within each individual patient may be targeted by the immune response, and to inject a large therapeutic bolus of attenuated MRTCs back into the patient. Tcelna consists of attenuated antigen specific Myelin Reactive T-cells, and the injection is meant to educate the body's immune system to recognize the similar MRTCs as "foreign" and destroy them.
 

           Continue




MS Views and News
Providing educational information, resources and services for those affected by MS

No comments: